243 related articles for article (PubMed ID: 24129975)
1. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
2. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
[TBL] [Abstract][Full Text] [Related]
3. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
4. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
5. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
Yan LX; Huang XF; Shao Q; Huang MY; Deng L; Wu QL; Zeng YX; Shao JY
RNA; 2008 Nov; 14(11):2348-60. PubMed ID: 18812439
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.
Tanic M; Yanowski K; Gómez-López G; Rodriguez-Pinilla MS; Marquez-Rodas I; Osorio A; Pisano DG; Martinez-Delgado B; Benítez J
Int J Cancer; 2015 Feb; 136(3):593-602. PubMed ID: 24917463
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
[TBL] [Abstract][Full Text] [Related]
9. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
10. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA in breast cancer: The association with BRCA1/2.
Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
[TBL] [Abstract][Full Text] [Related]
13. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
[TBL] [Abstract][Full Text] [Related]
14. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
15. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
16. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Alvarez C; Aravena A; Tapia T; Rozenblum E; Solís L; Corvalán A; Camus M; Alvarez M; Munroe D; Maass A; Carvallo P
BMC Cancer; 2016 Mar; 16():219. PubMed ID: 26979459
[TBL] [Abstract][Full Text] [Related]
17. MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
Danza K; De Summa S; Pinto R; Pilato B; Palumbo O; Merla G; Simone G; Tommasi S
Oncotarget; 2015 Jan; 6(1):471-83. PubMed ID: 25333258
[TBL] [Abstract][Full Text] [Related]
18. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
19. Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
Martinez-Delgado B; Gallardo M; Tanic M; Yanowsky K; Inglada-Perez L; Barroso A; Rodriguez-Pinilla M; Cañamero M; Blasco MA; Benitez J
Breast Cancer Res Treat; 2013 Sep; 141(2):231-42. PubMed ID: 24036693
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
Tanic M; Andrés E; Rodriguez-Pinilla SM; Marquez-Rodas I; Cebollero-Presmanes M; Fernandez V; Osorio A; Benítez J; Martinez-Delgado B
Br J Cancer; 2013 Nov; 109(10):2724-34. PubMed ID: 24104964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]